WO2022265380A1 - 히알루론산 가교체, 및 이를 포함하는 충전제 조성물 - Google Patents
히알루론산 가교체, 및 이를 포함하는 충전제 조성물 Download PDFInfo
- Publication number
- WO2022265380A1 WO2022265380A1 PCT/KR2022/008447 KR2022008447W WO2022265380A1 WO 2022265380 A1 WO2022265380 A1 WO 2022265380A1 KR 2022008447 W KR2022008447 W KR 2022008447W WO 2022265380 A1 WO2022265380 A1 WO 2022265380A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hyaluronic acid
- diglycidyl ether
- composition
- crosslinked product
- gel
- Prior art date
Links
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 124
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 122
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 122
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 239000000945 filler Substances 0.000 title claims abstract description 33
- 230000008961 swelling Effects 0.000 claims abstract description 30
- 239000007924 injection Substances 0.000 claims description 39
- 238000002347 injection Methods 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 16
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- 239000003431 cross linking reagent Substances 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- 230000003416 augmentation Effects 0.000 claims description 8
- 230000001588 bifunctional effect Effects 0.000 claims description 6
- 210000000481 breast Anatomy 0.000 claims description 6
- 125000003700 epoxy group Chemical group 0.000 claims description 6
- 230000001815 facial effect Effects 0.000 claims description 6
- IVIDDMGBRCPGLJ-UHFFFAOYSA-N 2,3-bis(oxiran-2-ylmethoxy)propan-1-ol Chemical compound C1OC1COC(CO)COCC1CO1 IVIDDMGBRCPGLJ-UHFFFAOYSA-N 0.000 claims description 3
- AOBIOSPNXBMOAT-UHFFFAOYSA-N 2-[2-(oxiran-2-ylmethoxy)ethoxymethyl]oxirane Chemical compound C1OC1COCCOCC1CO1 AOBIOSPNXBMOAT-UHFFFAOYSA-N 0.000 claims description 3
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 claims description 3
- WTYYGFLRBWMFRY-UHFFFAOYSA-N 2-[6-(oxiran-2-ylmethoxy)hexoxymethyl]oxirane Chemical compound C1OC1COCCCCCCOCC1CO1 WTYYGFLRBWMFRY-UHFFFAOYSA-N 0.000 claims description 3
- MECNWXGGNCJFQJ-UHFFFAOYSA-N 3-piperidin-1-ylpropane-1,2-diol Chemical compound OCC(O)CN1CCCCC1 MECNWXGGNCJFQJ-UHFFFAOYSA-N 0.000 claims description 3
- 206010046543 Urinary incontinence Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 238000002316 cosmetic surgery Methods 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 239000003589 local anesthetic agent Substances 0.000 claims description 3
- 210000003899 penis Anatomy 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920000223 polyglycerol Polymers 0.000 claims description 3
- 229920001451 polypropylene glycol Polymers 0.000 claims description 3
- 230000037303 wrinkles Effects 0.000 claims description 3
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 claims 2
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 claims 1
- 239000000853 adhesive Substances 0.000 abstract description 8
- 230000001070 adhesive effect Effects 0.000 abstract description 8
- 239000000499 gel Substances 0.000 description 46
- 239000000047 product Substances 0.000 description 31
- 239000000243 solution Substances 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- -1 poly(ethylene glycol) Polymers 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000000502 dialysis Methods 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 238000000691 measurement method Methods 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 4
- 230000003444 anaesthetic effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 229960004194 lidocaine Drugs 0.000 description 4
- 229940071643 prefilled syringe Drugs 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000004971 Cross linker Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920001954 Restylane Polymers 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- HPILSDOMLLYBQF-UHFFFAOYSA-N 2-[1-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COC(CCC)OCC1CO1 HPILSDOMLLYBQF-UHFFFAOYSA-N 0.000 description 2
- KUAUJXBLDYVELT-UHFFFAOYSA-N 2-[[2,2-dimethyl-3-(oxiran-2-ylmethoxy)propoxy]methyl]oxirane Chemical compound C1OC1COCC(C)(C)COCC1CO1 KUAUJXBLDYVELT-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- RFPVXZWXDPIKSD-UHFFFAOYSA-N [2-(diethylamino)-4-methylpentyl] 4-aminobenzoate;methanesulfonic acid Chemical compound CS(O)(=O)=O.CCN(CC)C(CC(C)C)COC(=O)C1=CC=C(N)C=C1 RFPVXZWXDPIKSD-UHFFFAOYSA-N 0.000 description 2
- VPRGXNLHFBBDFS-UHFFFAOYSA-N [3-(diethylamino)-1-phenylpropyl] benzoate Chemical compound C=1C=CC=CC=1C(CCN(CC)CC)OC(=O)C1=CC=CC=C1 VPRGXNLHFBBDFS-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000000385 dialysis solution Substances 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960004716 idoxuridine Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229950008865 propanocaine Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- HZGRVVUQEIBCMS-HTRCEHHLSA-N (1s,5r)-8-methyl-8-azabicyclo[3.2.1]oct-3-ene-4-carboxylic acid Chemical compound C1C=C(C(O)=O)[C@H]2CC[C@@H]1N2C HZGRVVUQEIBCMS-HTRCEHHLSA-N 0.000 description 1
- HGKAMARNFGKMLC-MOPGFXCFSA-N (2r)-2-[(4r)-2,2-diphenyl-1,3-dioxolan-4-yl]piperidine Chemical compound C([C@@H]1[C@H]2OC(OC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCN1 HGKAMARNFGKMLC-MOPGFXCFSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
- CAFOIGUDKPQBIO-BYIOMEFUSA-N (r)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-[6-(3-methylbutoxy)quinolin-4-yl]methanol Chemical compound C1=C(OCCC(C)C)C=C2C([C@@H](O)[C@@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 CAFOIGUDKPQBIO-BYIOMEFUSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- ZLMQPGUWYWFPEG-UHFFFAOYSA-N 2-(diethylamino)ethyl 4-amino-2-butoxybenzoate Chemical group CCCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC ZLMQPGUWYWFPEG-UHFFFAOYSA-N 0.000 description 1
- QNIUOGIMJWORNZ-UHFFFAOYSA-N 2-(diethylamino)ethyl 4-butoxybenzoate Chemical compound CCCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1 QNIUOGIMJWORNZ-UHFFFAOYSA-N 0.000 description 1
- PUYOAVGNCWPANW-UHFFFAOYSA-N 2-methylpropyl 4-aminobenzoate Chemical compound CC(C)COC(=O)C1=CC=C(N)C=C1 PUYOAVGNCWPANW-UHFFFAOYSA-N 0.000 description 1
- HQFWVSGBVLEQGA-UHFFFAOYSA-N 4-aminobenzoic acid 3-(dibutylamino)propyl ester Chemical compound CCCCN(CCCC)CCCOC(=O)C1=CC=C(N)C=C1 HQFWVSGBVLEQGA-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- NMPOSNRHZIWLLL-XUWVNRHRSA-N Cocaethylene Chemical group O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OCC)C(=O)C1=CC=CC=C1 NMPOSNRHZIWLLL-XUWVNRHRSA-N 0.000 description 1
- PHMBVCPLDPDESM-YWIQKCBGSA-N Ecgonine Natural products C1[C@H](O)[C@@H](C(O)=O)[C@H]2CC[C@@H]1N2C PHMBVCPLDPDESM-YWIQKCBGSA-N 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- DKLKMKYDWHYZTD-UHFFFAOYSA-N Hexylcaine Chemical compound C=1C=CC=CC=1C(=O)OC(C)CNC1CCCCC1 DKLKMKYDWHYZTD-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- YUGZHQHSNYIFLG-UHFFFAOYSA-N N-phenylcarbamic acid [2-[anilino(oxo)methoxy]-3-(1-piperidinyl)propyl] ester Chemical compound C1CCCCN1CC(OC(=O)NC=1C=CC=CC=1)COC(=O)NC1=CC=CC=C1 YUGZHQHSNYIFLG-UHFFFAOYSA-N 0.000 description 1
- VNQABZCSYCTZMS-UHFFFAOYSA-N Orthoform Chemical compound COC(=O)C1=CC=C(O)C(N)=C1 VNQABZCSYCTZMS-UHFFFAOYSA-N 0.000 description 1
- FTLDJPRFCGDUFH-UHFFFAOYSA-N Oxethazaine Chemical compound C=1C=CC=CC=1CC(C)(C)N(C)C(=O)CN(CCO)CC(=O)N(C)C(C)(C)CC1=CC=CC=C1 FTLDJPRFCGDUFH-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- YQKAVWCGQQXBGW-UHFFFAOYSA-N Piperocaine Chemical compound CC1CCCCN1CCCOC(=O)C1=CC=CC=C1 YQKAVWCGQQXBGW-UHFFFAOYSA-N 0.000 description 1
- 229920001363 Polidocanol Polymers 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- CAJIGINSTLKQMM-UHFFFAOYSA-N Propoxycaine Chemical compound CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC CAJIGINSTLKQMM-UHFFFAOYSA-N 0.000 description 1
- FDMBBCOBEAVDAO-UHFFFAOYSA-N Stovaine Chemical compound CN(C)CC(C)(CC)OC(=O)C1=CC=CC=C1 FDMBBCOBEAVDAO-UHFFFAOYSA-N 0.000 description 1
- 241000194048 Streptococcus equi Species 0.000 description 1
- 241000120569 Streptococcus equi subsp. zooepidemicus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- ZYHGIAPHLSTGMX-WCQYABFASA-N [(4r,6s)-2,2,6-trimethylpiperidin-4-yl] benzoate Chemical compound C1C(C)(C)N[C@@H](C)C[C@H]1OC(=O)C1=CC=CC=C1 ZYHGIAPHLSTGMX-WCQYABFASA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 229950008211 ambucaine Drugs 0.000 description 1
- 229950009452 amolanone Drugs 0.000 description 1
- HPITVGRITATAFY-UHFFFAOYSA-N amolanone Chemical compound O=C1OC2=CC=CC=C2C1(CCN(CC)CC)C1=CC=CC=C1 HPITVGRITATAFY-UHFFFAOYSA-N 0.000 description 1
- 229960000806 amylocaine Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229960003831 articaine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- VXJABHHJLXLNMP-UHFFFAOYSA-N benzoic acid [2-methyl-2-(propylamino)propyl] ester Chemical compound CCCNC(C)(C)COC(=O)C1=CC=CC=C1 VXJABHHJLXLNMP-UHFFFAOYSA-N 0.000 description 1
- 229950005028 betoxycaine Drugs 0.000 description 1
- CXYOBRKOFHQONJ-UHFFFAOYSA-N betoxycaine Chemical compound CCCCOC1=CC=C(C(=O)OCCOCCN(CC)CC)C=C1N CXYOBRKOFHQONJ-UHFFFAOYSA-N 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 229960003369 butacaine Drugs 0.000 description 1
- 229960000400 butamben Drugs 0.000 description 1
- IUWVALYLNVXWKX-UHFFFAOYSA-N butamben Chemical compound CCCCOC(=O)C1=CC=C(N)C=C1 IUWVALYLNVXWKX-UHFFFAOYSA-N 0.000 description 1
- 229960001290 butanilicaine Drugs 0.000 description 1
- VWYQKFLLGRBICZ-UHFFFAOYSA-N butanilicaine Chemical compound CCCCNCC(=O)NC1=C(C)C=CC=C1Cl VWYQKFLLGRBICZ-UHFFFAOYSA-N 0.000 description 1
- 229950009376 butethamine Drugs 0.000 description 1
- WDICTQVBXKADBP-UHFFFAOYSA-N butethamine Chemical compound CC(C)CNCCOC(=O)C1=CC=C(N)C=C1 WDICTQVBXKADBP-UHFFFAOYSA-N 0.000 description 1
- 229960002463 butoxycaine Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960004741 cyclomethycaine Drugs 0.000 description 1
- YLRNESBGEGGQBK-UHFFFAOYSA-N cyclomethycaine Chemical compound CC1CCCCN1CCCOC(=O)C(C=C1)=CC=C1OC1CCCCC1 YLRNESBGEGGQBK-UHFFFAOYSA-N 0.000 description 1
- PHMBVCPLDPDESM-UHFFFAOYSA-N d-Pseudoekgonin Natural products C1C(O)C(C(O)=O)C2CCC1N2C PHMBVCPLDPDESM-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- OWQIUQKMMPDHQQ-UHFFFAOYSA-N dimethocaine Chemical compound CCN(CC)CC(C)(C)COC(=O)C1=CC=C(N)C=C1 OWQIUQKMMPDHQQ-UHFFFAOYSA-N 0.000 description 1
- 229950010160 dimethocaine Drugs 0.000 description 1
- 229960002228 diperodon Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- PHMBVCPLDPDESM-FKSUSPILSA-N ecgonine Chemical compound C1[C@H](O)[C@H](C(O)=O)[C@H]2CC[C@@H]1N2C PHMBVCPLDPDESM-FKSUSPILSA-N 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 229960003976 etidocaine Drugs 0.000 description 1
- 229950008467 euprocin Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960005388 hexylcaine Drugs 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- DHCUQNSUUYMFGX-UHFFFAOYSA-N hydroxytetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C(O)=C1 DHCUQNSUUYMFGX-UHFFFAOYSA-N 0.000 description 1
- 229950000638 hydroxytetracaine Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229950003548 levoxadrol Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229950007594 meprylcaine Drugs 0.000 description 1
- 229950004316 metabutoxycaine Drugs 0.000 description 1
- LJQWYEFHNLTPBZ-UHFFFAOYSA-N metabutoxycaine Chemical compound CCCCOC1=C(N)C=CC=C1C(=O)OCCN(CC)CC LJQWYEFHNLTPBZ-UHFFFAOYSA-N 0.000 description 1
- ZPUCINDJVBIVPJ-XGUBFFRZSA-N methyl (1s,3s,4s,5r)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-XGUBFFRZSA-N 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960000739 myrtecaine Drugs 0.000 description 1
- BZRYYBWNOUALTQ-HOTGVXAUSA-N myrtecaine Chemical compound CCN(CC)CCOCCC1=CC[C@@H]2C(C)(C)[C@H]1C2 BZRYYBWNOUALTQ-HOTGVXAUSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- UYXHCVFXDBNRQW-UHFFFAOYSA-N naepaine Chemical compound CCCCCNCCOC(=O)C1=CC=C(N)C=C1 UYXHCVFXDBNRQW-UHFFFAOYSA-N 0.000 description 1
- 229950009121 naepaine Drugs 0.000 description 1
- 229950009333 octacaine Drugs 0.000 description 1
- HKOURKRGAFKVFP-UHFFFAOYSA-N octacaine Chemical compound CCN(CC)C(C)CC(=O)NC1=CC=CC=C1 HKOURKRGAFKVFP-UHFFFAOYSA-N 0.000 description 1
- 229950006098 orthocaine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229960000986 oxetacaine Drugs 0.000 description 1
- 229960003502 oxybuprocaine Drugs 0.000 description 1
- CMHHMUWAYWTMGS-UHFFFAOYSA-N oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 description 1
- 229960003899 parethoxycaine Drugs 0.000 description 1
- OWWVHQUOYSPNNE-UHFFFAOYSA-N parethoxycaine Chemical compound CCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1 OWWVHQUOYSPNNE-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229950007049 phenacaine Drugs 0.000 description 1
- QXDAEKSDNVPFJG-UHFFFAOYSA-N phenacaine Chemical compound C1=CC(OCC)=CC=C1N\C(C)=N\C1=CC=C(OCC)C=C1 QXDAEKSDNVPFJG-UHFFFAOYSA-N 0.000 description 1
- 229960001045 piperocaine Drugs 0.000 description 1
- 229960002226 polidocanol Drugs 0.000 description 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960001896 pramocaine Drugs 0.000 description 1
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- STHAHFPLLHRRRO-UHFFFAOYSA-N propipocaine Chemical compound C1=CC(OCCC)=CC=C1C(=O)CCN1CCCCC1 STHAHFPLLHRRRO-UHFFFAOYSA-N 0.000 description 1
- 229950011219 propipocaine Drugs 0.000 description 1
- 229950003255 propoxycaine Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- OYCGKECKIVYHTN-UHFFFAOYSA-N pyrrocaine Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCCC1 OYCGKECKIVYHTN-UHFFFAOYSA-N 0.000 description 1
- 229950000332 pyrrocaine Drugs 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229960001549 ropivacaine Drugs 0.000 description 1
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- UDKICLZCJWQTLS-UHFFFAOYSA-N tolycaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C(=O)OC UDKICLZCJWQTLS-UHFFFAOYSA-N 0.000 description 1
- 229950006609 tolycaine Drugs 0.000 description 1
- GOZBHBFUQHMKQB-UHFFFAOYSA-N trimecaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=C(C)C=C1C GOZBHBFUQHMKQB-UHFFFAOYSA-N 0.000 description 1
- 229950002569 trimecaine Drugs 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 229960003434 xenysalate Drugs 0.000 description 1
- HLDCSYXMVXILQC-UHFFFAOYSA-N xenysalate Chemical compound CCN(CC)CCOC(=O)C1=CC=CC(C=2C=CC=CC=2)=C1O HLDCSYXMVXILQC-UHFFFAOYSA-N 0.000 description 1
- KYBJXENQEZJILU-UHFFFAOYSA-N zolamine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=NC=CS1 KYBJXENQEZJILU-UHFFFAOYSA-N 0.000 description 1
- 229950006211 zolamine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/15—Heterocyclic compounds having oxygen in the ring
- C08K5/151—Heterocyclic compounds having oxygen in the ring having one oxygen atom in the ring
- C08K5/1515—Three-membered rings
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
Definitions
- the present disclosure relates to a crosslinked hyaluronic acid and a filler composition comprising the same, and more specifically, to a crosslinked hyaluronic acid having high cohesion and adhesive strength and reduced swelling, and a filler composition comprising the same.
- Hyaluronic acid is a linear polysaccharide that generally has a high average molecular weight.
- Hyaluronic acid is a negatively charged polymer of D-glucuronic acid and N-acetyl-D-glucosamine.
- Hyaluronic acid is found primarily in the extracellular matrix and intercellular matrix, but is also present intracellularly.
- hyaluronic acid is a substance that already exists in the body, it has biocompatibility and also has characteristics that make it easy to prepare a crosslinked hyaluronic acid hydrogel using a crosslinking agent or the like. For this reason, filler products using cross-linked hyaluronic acid have been widely used worldwide since Galderma first released Restylane products in the 1990s.
- the hyaluronic acid gel currently used as a filler is prepared by chemically crosslinking natural hyaluronic acid into a network through a crosslinking reaction. Natural hyaluronic acid and certain partially cross-linked hyaluronic acids absorb water until they are completely dissolved in water, but cross-linked hyaluronic acid gels typically absorb a certain amount of water until they are saturated, and thus have a limited degree of swelling. degree).
- filler products using cross-linked hyaluronic acid gel can be classified as having a monophasic or biphasic phase.
- the single-phase cross-linked hyaluronic acid gel has a high viscous modulus and a low elastic modulus.
- the two-phase cross-linked hyaluronic acid gel has a low viscous modulus and a high elastic modulus.
- a single-phase cross-linked hyaluronic acid gel and a two-phase cross-linked hyaluronic acid gel have different properties in vivo. For example, single-phase cross-linked hyaluronic acid gels with a low elastic modulus and a high viscous modulus have excellent cohesion and are unlikely to escape from the injected site.
- the single-phase crosslinked hyaluronic acid gel generally has a disadvantage in that the volume increases compared to the previously injected volume without maintaining the original shape injected at the initial stage of injection when injected into the body.
- the isomeric cross-linked hyaluronic acid gel which has a high elastic modulus but a low viscous modulus, can maintain the injected form for a long period of time with a small volume change, but has the characteristics of being easily separated from the injected site or not evenly distributed at the injected site.
- swelling may occur after the hyaluronic acid filler procedure, which refers to a phenomenon in which the hyaluronic acid gel component injected into the body absorbs bodily fluid from the tissue surrounding the injection site and the injected site and surrounding areas swell.
- This swelling phenomenon is one of the common side effects of the filler procedure in that the injection site is swollen, and it is preferable in that the viscosity, elasticity, and strength of the hyaluronic acid gel may decrease due to absorbed water, thereby reducing the injection effect of the filler. It is a phenomenon that has not been
- One object of the present disclosure is to provide a hyaluronic acid crosslinked product having a critical strain of 10% to 100% and a swelling degree of 1% to 100%.
- Another object of the present disclosure is to provide a filler composition comprising the hyaluronic acid crosslinked product.
- One aspect of the present disclosure provides a hyaluronic acid crosslinked product having a critical strain of 10% to 100% and a swelling degree of 1% to 100%.
- the hyaluronic acid crosslinked product may have an average particle size ranging from 50 um to 150 um.
- the hyaluronic acid crosslinked product may have an elastic modulus (G') of 400 Pa to 2,000 Pa.
- the hyaluronic acid crosslinked product may have a viscosity modulus (G") of 100 Pa to 600 Pa.
- the hyaluronic acid crosslinked product may have a compressive force of 15 N ⁇ s to 100 N ⁇ s.
- the hyaluronic acid crosslinked product may have an injection force of 1 N to 50 N.
- the hyaluronic acid crosslinker may be crosslinked with a crosslinker having a bifunctional epoxy group.
- the crosslinking agent having the bifunctional epoxy group is 1,4-butanediol diglycidyl ether, poly(ethylene glycol) diglycidyl ether, poly(propylene glycol) diglycidyl ether, poly(tetramethylene glycol) diglycidyl Dyl ether, polyglycerol polyglycidyl ether, glycerol diglycidyl ether, triethylene diglycidyl ether, trimethylolpropane triglycidyl ether, ethylene diglycidyl ether, neopentyl glycol diglycidyl ether, And it may be at least one selected from the group consisting of 1,6-hexanediol diglycidyl ether.
- Another aspect of the present disclosure provides a filler composition comprising the hyaluronic acid crosslinked product.
- the concentration of the hyaluronic acid crosslinker in the filler composition may be 10 mg/mL to 30 mg/mL.
- the filler composition may not further comprise uncrosslinked hyaluronic acid.
- the filler composition may further include a local anesthetic.
- the filler composition may be filled into a syringe.
- the filler composition may be used for one or more purposes selected from the group consisting of facial plastic surgery, wrinkle improvement, facial contouring, breast augmentation, breast augmentation, penis enlargement, glans enlargement, urinary incontinence treatment, and arthritis treatment.
- the crosslinked hyaluronic acid gel according to the present disclosure has high cohesion and adhesive strength, it is characterized in that it is maintained intact without separation from the injection site and at the same time, the swelling phenomenon after injection is reduced.
- FIG. 1 is a view showing the volume of the injected hyaluronic acid gel according to the time elapsed after injection after a cross-linked hyaluronic acid sample was injected into a hairless mouse.
- the present disclosure generally provides a hyaluronic acid crosslinked product having a critical strain of 10% to 100% and a swelling degree of 1% to 100%.
- hyaluronic acid refers to hyaluronan, hyaluronate, or a pharmaceutically acceptable salt thereof having the formula 1:
- n is the number of repeating units.
- the hyaluronic acid may be of any origin. Hyaluronic acid may be of animal or non-animal origin, for example.
- the hyaluronic acid may also be of bacterial origin.
- the bacteria may be from the genus Streptococcus .
- the bacteria of the genus Streptococcus may be Streptococcus equi , S. pyogenes or S. zooepidemicus .
- the hyaluronic acid may also be purchased commercially.
- the molecular weight of the hyaluronic acid may be 1,000,000 Da to 2,500,000 Da, for example, 1,000,000 Da to 2,000,000 Da, 1,500,000 Da to 2,500,000 Da, or 1,500,000 Da to 2,000,000 Da.
- the intrinsic viscosity of the hyaluronic acid is 1.0 m 3 /kg to 5.0 m 3 /kg, for example, 1.5 m 3 /kg to 4.0 m 3 /kg, 2.5 m 3 /kg to 4.0 m 3 /kg, 2.5 m 3 /kg to 3.5 m 3 /kg, or 2.5 m 3 /kg to 3.0 m 3 /kg.
- hyaluronic acid crosslinked product refers to crosslinked hyaluronic acid
- hyaluronic acid crosslinked product crosslinked hyaluronic acid
- crosslinked hyaluronic acid crosslinked hyaluronic acid
- swelling refers to a phenomenon in which the cross-linked hyaluronic acid gel absorbs water and swells.
- the term swelling degree refers to the ratio of the weight of the cross-linked hyaluronic acid gel completely swollen to that before swelling when the cross-linked hyaluronic acid is immersed in water.
- the degree of swelling can be obtained, for example, according to the calculation formula described in the Measurement Methods section below.
- critical strain is a measurement index for confirming a strain value required to cause destruction of the internal structure of a material including linear viscoelastic properties when a shear strain is applied to the material.
- a crosslinked hyaluronic acid gel is composed of a crosslinked hyaluronic acid gel or a crosslinked hyaluronic acid gel and a solution, and various internal interaction forces such as hydrogen bonds, covalent bonds, van der Waals bonds, and physical bonds exist inside them. exist. Internal interactions can be classified as gel-gel, gel-solution, or solution-solution interactions.
- the molecular fluidity is higher than that of a gel, and the contact area is smaller than that of a gel, so the size of the interaction is It can be thought of as gel-gel > gel-solution > solution-solution.
- gel-gel > gel-solution > solution-solution In the case of a single phase in which only a gel-gel form exists, it can be expected that the internal structure is destroyed at a higher strain rate because it has a relatively high interaction.
- the gel and the solution exist together since the gel and the solution exist together, the gel-gel interaction is reduced, whereas the total of the interactions of the internal structure is larger than that of the single phase because the gel-solution interaction and the solution-solution interaction are larger. Since it is expected to be smaller when strained, it can be expected that the internal structure will fail at lower strains.
- the hyaluronic acid crosslinked product according to one aspect of the present disclosure exhibits unexpected properties in that it has a high critical strain rate like conventional single-phase hyaluronic acid fillers, but has a low degree of swelling.
- the hyaluronic acid crosslinked product of the present disclosure has high cohesive force and high adhesive force similar to conventional single-phase fillers, so it does not easily separate from the injection site and can maintain the injected shape for a long period of time due to its high elastic modulus (G'). It is characterized by having
- a hyaluronic acid crosslinked product according to the present disclosure has (i) a critical strain of 10% to 100%, such as 10% to 50%, 10% to 30%, or 10% to 40%, such as 10% to 50%. 50%, for example 10% to 30%, with a swelling degree of 1% to 100%, for example 1% to 90%, 1% to 80%, 1% to 70%, 1% to 60%, 1% to 50%, 10% to 60%, 20% to 60%, 30% to 60%, 40% to 60%, 40% to 50%, and 50% to 60%.
- a critical strain of 10% to 100% such as 10% to 50%, 10% to 30%, or 10% to 40%, such as 10% to 50%.
- 50% for example 10% to 30%
- a swelling degree of 1% to 100% for example 1% to 90%, 1% to 80%, 1% to 70%, 1% to 60%, 1% to 50%, 10% to 60%, 20% to 60%, 30% to 60%, 40% to 60%, 40% to 50%, and 50% to 60%.
- the hyaluronic acid crosslinked product (ii) has an average particle size (um) of 50 um to 150 um, for example, 60 um to 150 um, 70 um to 150 um, 80 um to 150 um, 90 um to 150 um, 60 um to 140 um, 60 um to 130 um, 60 um to 120 um, and 60 um to 100 um.
- the hyaluronic acid crosslinked product (iii) may have an elastic modulus (G′) of 400 Pa to 2,000 Pa, for example, 500 Pa to 1,900 Pa, 600 Pa to 1,800 Pa, or 600 Pa to 1,700 Pa.
- G′ elastic modulus
- the hyaluronic acid crosslinked product may have (iv) a viscosity coefficient (G") of 100 Pa to 600 Pa, for example, 120 Pa to 500 Pa, 150 Pa to 450 Pa, or 160 Pa to 350 Pa.
- G viscosity coefficient
- the hyaluronic acid crosslinked product (v) has a compression of 15 N ⁇ s to 100 N ⁇ s, for example, 20 N ⁇ s to 90 N ⁇ s, 25 N ⁇ s to 80 N ⁇ s, or 30 N ⁇ s N ⁇ s to 75 N ⁇ s.
- the hyaluronic acid crosslinked product (vi) may have an injection force of 1 N to 50 N, for example, 3 N to 45 N, 4 N to 40 N, or 7 N to 35 N.
- the hyaluronic acid crosslinked product may satisfy one, two, three, four or five of the requirements (ii) to (vi) while satisfying the requirement (i).
- the hyaluronic acid crosslinked product according to the present disclosure may be, for example, prepared by a process comprising the following steps, but is not limited thereto:
- steps (b) to (d) in the above process steps may be changed or may be repeated two or more times.
- the milling step may be additionally carried out between steps (a) and (b) in addition to step (c), or may be carried out only in step (c), or steps (a) and (b) instead of step (c). (b) can only be practiced.
- steps (a) to (d) may be further included, for example, adding an anesthetic agent as described below, and/or performing high-temperature steam sterilization.
- adding an anesthetic may be added between steps (b) and (c), or between steps (c) and (d).
- the step of performing high-temperature steam sterilization may be added between steps (c) and (d) above or after step (d).
- the aqueous alkali solution may be NaOH, KOH, preferably NaOH aqueous solution, but is not limited thereto.
- the concentration is 0.1% (w/w) to 2.5% (w/w), such as 0.1% (w/w) to 2.0% (w/w), or 0.5% (w/w). ) to 1.0% (w/w).
- the concentration of hyaluronic acid dissolved in the aqueous alkali solution is 10% (w / w) to 25% (w / w), for example, 10% (w / w) to 20% (w / w) or 10% (w/w) to 15% (w/w).
- the crosslinking agent may have a multifunctional group.
- the crosslinking agent may have a bifunctional epoxy group.
- the crosslinking agent having the bifunctional epoxy group is 1,4-butanediol diglycidyl ether, poly(ethylene glycol) diglycidyl ether, poly(propylene glycol) diglycidyl ether, poly(tetramethylene glycol) diglycidyl Dyl ether, polyglycerol polyglycidyl ether, glycerol diglycidyl ether, triethylene diglycidyl ether, trimethylolpropane triglycidyl ether, ethylene diglycidyl ether, neopentyl glycol diglycidyl ether, And it may be at least one selected from the group consisting of 1,6-hexanediol diglycidyl ether.
- the crosslinking reaction may be at room temperature or higher, for example, 20 ° C to 40 ° C, 25 ° C to 40 ° C, or 30 ° C to 40 ° C, and the reaction time is 24 hours or less, for example, 10 to 24 hours, It may be 15 to 24 hours, or 15 to 20 hours.
- the dialysis is carried out by mixing the crosslinked gel with a dialysis solution containing a predetermined buffer solution such as NaCl solution, KOH solution, PBS solution, etc. in a dialysis membrane or dialysis vessel, dialysis, washing, and dialysis.
- a dialysis solution containing a predetermined buffer solution such as NaCl solution, KOH solution, PBS solution, etc.
- a dialysis membrane or dialysis vessel alysis membrane or dialysis vessel
- dialysis, washing, and dialysis Refers to the step of swelling the gel.
- This series of dialysis, washing and expansion steps may be repeated two or more times.
- unreacted cross-linking agent may be removed and/or pH and/or osmotic pressure of the cross-linked gel may be adjusted.
- the grinding is performed using a grinder at 1,000 to 10,000 rpm, for example, 2,000 to 9,000 rpm, 3,000 to 8,000 rpm, 4,000 to 7,000 rpm, 5,000 to 9,000 rpm, or 5,000 to 8,000 rpm for 60 seconds or more. , For example, it may be performed for 60 seconds to 100 seconds, 70 seconds to 120 seconds, 80 seconds to 140 seconds, 90 seconds to 160 seconds, 100 seconds to 180 seconds, 120 seconds to 240 seconds.
- Another aspect provides a filler composition comprising the above hyaluronic acid crosslinked product.
- the final concentration of the crosslinked hyaluronic acid gel may be 10 mg/ml or more, 15 mg/ml or more, 18 mg/ml or more, or 19 mg/ml or more.
- the concentration of the cross-linked hyaluronic acid is 10 mg/ml to 30 mg/ml, 12 mg/ml to 28 mg/ml, 14 mg/ml to 26 mg/ml, 16 mg/ml to 24 mg/ml ml, 16 mg/ml to 20 mg/ml, or about 18 mg/ml.
- the composition may not additionally include uncrosslinked hyaluronic acid.
- "Additionally including" uncrosslinked hyaluronic acid means artificially adding more uncrosslinked hyaluronic acid to the crosslinked hyaluronic acid, and not additionally including uncrosslinked hyaluronic acid means crosslinking hyaluronic acid. It means not artificially adding more uncrosslinked hyaluronic acid to the body.
- the composition may further contain an anesthetic.
- the anesthetic may be a local anesthetic.
- the anesthetic agent is ambucaine, amolanone, amylocaine, benoxinate, benzocaine, betoxycaine, biphenamine, Bupivacaine, butacaine, butamben, butanilicaine, butethamine, butoxycaine, carticaine, chloroprocaine ), cocaethylene, cocaine, cyclomethycaine, dibucaine, dimethysoquin, dimethocaine, diperodon, cyclonine, ecgonidine, ecgonine, ethyl chloride, etidocaine, beta-eucaine, euprocin, phenalcomine, formocaine, hexylcaine, hydroxytetracaine, isobutyl p-aminobenzoate, leucinocaine mesylate, leucinocaine mesylate le
- the composition may not contain a pharmaceutically active substance selected from the group consisting of proteins, hyaluronic acid and other glycosaminoglycans, and hydroxypropyl methyl cellulose.
- the composition may be filled in a syringe.
- composition may be used for tissue repair in a subject.
- the subject may be a mammal.
- the mammal may be a human, dog, cat, cow, pig, rat, or sheep.
- the composition may be used for one or more purposes selected from the group consisting of facial plastic surgery, wrinkle improvement, facial contouring, breast augmentation, breast augmentation, penis enlargement, glans enlargement, urinary incontinence treatment, and arthritis treatment.
- the composition may further include pharmaceutically acceptable carriers, excipients and diluents.
- the carrier may include, for example, water or a buffer.
- the buffer may be such that the pH of the solution hardly changes with the addition of the components of the composition.
- the composition may be an aqueous liquid composition.
- the composition may be an aqueous buffered composition.
- the pH of the aqueous buffered composition may be in the physiological pH range, for example between about 6.0 and 8.0. The pH can be adjusted by adding a suitable acid or base such as HCl, Na 2 CO 3 or NaOH.
- the aqueous buffered composition may include phosphate buffered saline (PBS).
- the aqueous buffered composition may include tris(hydroxymethyl)aminomethane (Tris).
- Tris tris(hydroxymethyl)aminomethane
- additional solutes such as sodium chloride, calcium chloride, and potassium chloride, may be added to adjust the osmolarity and ion concentration.
- the composition may be sterile.
- the composition may be contained in a container.
- the container may be a syringe.
- the composition may be pre-filled into a syringe before use.
- the composition may be administered with a pre-filled syringe.
- the device may be a pre-filled syringe.
- the device may be sterile.
- kits comprising the pre-filled syringe described above.
- the kit may include instructions including information on administering the composition.
- Another aspect provides a method of filling tissue of a subject comprising administering to the subject a therapeutically effective amount of a composition described above.
- the method may be for augmentation, repair or consolidation of a subject's tissue or filling of a body cavity. Volume augmentation in this respect may be a long lasting increase in volume by a component forming the filler composition. Components forming the filler composition may not undergo rapid diffusion.
- “composition” and “individual” are as described above.
- the administration may be administered within the skin or joint cavity, such as in the dermis.
- the administration may be administration through a syringe, eg, a pre-filled syringe into the skin, eg, into the dermis.
- the administration may be administration of 0.1 to 50ml, 0.5 to 30ml, 0.5 to 20ml, 0.5 to 15ml, or 0.8 to 12ml per time.
- the administration comprises administering the composition once per period of 3 months or longer, once for 4 months or longer, once for 5 months or longer, once for 6 months or longer, once for 12 months or longer, or It may be administration once per period of 18 months or more.
- Critical strain was measured by strain-sweep test. Specifically, a DHR-2 rheometer instrument (TA Instruments) was driven. In the strain-sweep test, calibration was performed by setting the instrument temperature to 25° C. and mounting a 25 mm diameter geometry. An appropriate amount of sample was loaded centrally between the upper and lower geometries of the Peltier plates of the instrument. A sufficient amount of the sample was over-loaded so as not to be insufficient, and an appropriate amount was loaded so that the residue outside the lower area of the geometry was not smeared on the side and upper surfaces of the geometry. After the geometry was lowered to the set distance, it was confirmed that the sample was well filled under the geometry, and then the remaining sample outside the geometry was removed by trimming.
- strain % strain %
- elastic modulus Storage Modulus, Pa
- Transform function converts strain % (strain (%)) value into log (strain (%)), and in order to easily check the minimum strain % (Strain, %) from the obtained value, the program’s built-in Smooth function logs log After calculating the smooth graph of the change in the elastic modulus (Storage Modulus, Pa) for the (strain (%)) value, the strain % (strain (%)) is the value before taking log (strain (%)) with the Transform function. ) was converted to From the data obtained through the above process, the amount of change in the storage modulus (Pa) value according to the strain % (Strain, %) can be confirmed. At this time, the strain % (Strain, %) of the minimum elastic modulus value was defined as the critical strain. .
- Hyaluronic acid gel was added to the conical tube and weighed to record the initial weight.
- 5.0 mL of PBS solution (pH 7.4) was added to the conical tube, vortexed for 1 minute to homogeneously mix, and then completely sealed and incubated at room temperature for 24 hours to swell the hyaluronic acid gel.
- 200 ⁇ L of Alcian Blue Solution was added to the swollen hyaluronic acid gel in the conical tube, and after vortexing for 1 minute, incubation was performed at room temperature for 30 minutes to stain the hyaluronic acid gel.
- the hyaluronic acid gel was precipitated by centrifugation at 14000 g at 4° C.
- Average particle size measurement is performed using Microtrac's Particle Size Analyzer S3500. Average particle size measurement is performed by adding a sample to a solvent, and is performed using laser diffraction analysis. The solvent is measured using distilled water. After thoroughly washing the sample inlet with distilled water before performing, enter the refractive index of distilled water and the refractive index of the sample as 1.33 and 1.37, respectively, and set the sample type as transparent and irregularly shaped particles. Before measurement, after filling the sample inlet of the device with distilled water, inserting the sample into a tube, etc., diluting it with an excess of distilled water, dispersing the sample sufficiently using a vortex, etc., and then inserting it into the device for measurement. Among the measurement results, the average particle size (D50) was used as data.
- a DHR-2 rheometer instrument (TA instruments) was driven.
- the viscoelasticity test was calibrated by setting the instrument temperature to 25°C and mounting a 40 mm diameter geometry. An appropriate amount of sample was loaded centrally between the upper and lower geometries of the Peltier plates of the instrument. A sufficient amount of the sample was overloaded so as not to be insufficient, and an appropriate amount was loaded to the extent that it did not smudge the top and side surfaces of the geometry. After the geometry was lowered to the set distance, it was checked whether the sample was filled under the geometry, and then the remaining sample outside the geometry was cut away and removed.
- Adhesion was measured as follows. A DHR-2 rheometer instrument (TA instruments) was driven. The adhesion test was performed by setting the instrument temperature to 25 ° C and mounting a 40 mm diameter geometry. An appropriate amount of sample was loaded centrally between the upper and lower geometries of the Peltier plates of the instrument. A sufficient amount of the sample was overloaded so as not to be insufficient, and an appropriate amount was loaded to the extent that it did not smudge the top and side surfaces of the geometry. After the geometry was lowered to the set distance, it was checked whether the sample was well filled under the geometry, and then the remaining sample outside the geometry was cut away and removed.
- TA instruments DHR-2 rheometer instrument
- the force applied to the geometry was measured when the geometry gap was pulled at a constant speed of 100.0 um/s in the vertical axis direction from the lower Peltier plate to a height of 1000 um for 180 seconds. Due to the adhesive force of the sample between the geometry and the Peltier plate, the largest force was measured at the moment the initial sample fell, and the force was defined as the adhesive force.
- a DHR-2 rheometer instrument (TA instruments) was driven.
- the compression force test was calibrated by setting the instrument temperature to 25°C and mounting a 25 mm diameter geometry. A sample of 1 mL was loaded centrally between the upper and lower geometries of the Peltier plate of the instrument. After lowering the geometry to the set interval, the geometry was rotated at a slow speed to adjust the sample to come to the center of the geometry standard. Then, the force applied to the geometry was measured while lowering the geometry from 2500 um to 900 um at a constant speed of 13.33 um/s.
- Compressive force was defined as a value corresponding to the value of the area under the graph, which is the integral value of the graph when a graph with the force measured from the start to the end of the test as the Y axis and the movement time as the X axis was drawn.
- Injection force measurement was measured using Mecmesin's Multitest 2.5-i Universal Testing Machine.
- a load cell to measure the force applied to the device was used by installing an appropriate load cell with a tolerance higher than the injection force measurement range.
- a syringe containing a sample was placed under the load cell of the device, and a needle was coupled to the syringe.
- a push rod with a flat end was placed on the syringe so that a constant force could be applied when the load cell applied force. After adjusting the distance until just before the load cell part touches the tip of the push rod, the load cell was pressed at a speed of 12 mm/min to measure the applied force.
- the pressure value generated when the sample flows into the needle is lower than the pressure required when injecting the syringe.
- the applied force is a force that is not related to the injection force of the sample. Therefore, the value measured excluding the value corresponding to the part where the sample flows into the needle and the part where the injection is almost completed Average of the injection force values measured in the middle part of the syringe filling liquid excluding the initial injection force and final injection force values was defined as the injection power.
- a hyaluronic acid crosslinked product having a critical strain of 10% to 100% and a swelling degree of 1% to 100% was prepared as follows.
- a 1% (w/w) NaOH solution was prepared.
- 5 g of sodium hyaluronate (IV 2.2 to 3.0) was mixed with the prepared 1% NaOH solution to a concentration of 13.00% (w/w), and then stirred to sufficiently dissolve.
- IV represents the intrinsic viscosity.
- 0.630 g of butanediol diglycidyl ether (BDDE) (Sigma-Aldrich) was added to the solution and further stirred to mix well, then taken out and crosslinked at 40 ° C. for 16 to 20 hours The reaction proceeded to prepare a cross-linked hyaluronic acid gel.
- BDDE butanediol diglycidyl ether
- the obtained cross-linked gel was placed in a dialysis membrane, sealed, and dialysis was performed using 1 mol/kg aqueous NaCl solution and 1x PBS aqueous solution as dialysis solutions to remove unreacted cross-linking agent.
- content correction was performed using 1x PBS so that the final concentration of sodium hyaluronate removed in consideration of the loss rate from the weight of the initially introduced sodium hyaluronate was 18 mg/mL.
- the content was corrected to be 3 mg/mL.
- Example 1 a PBS solution containing 18 mg/mL of cross-linked hyaluronic acid and 3 mg/mL of lidocaine was prepared. Grinding was performed at 8000 rpm for 180 seconds using the prepared cross-linked hyaluronic acid-containing solution using a mixer (Retsch GM-200). Thereafter, 1 ml of the pulverized cross-linked hyaluronic acid-containing solution was filled into a glass syringe, followed by high-temperature steam sterilization. The material obtained through this process was designated as Example 1.
- Example 2 the crosslinked hyaluronic acid-containing solution was prepared in the same manner as in Example 1 except that grinding was performed at 5000 rpm for 75 seconds using a mixer (Retsch GM-200).
- Comparative Example 1 was prepared in the same manner as in Example 1 except that the cross-linked hyaluronic acid-containing solution was pulverized at 2000 rpm for 180 seconds using a mixer (Retsch GM-200).
- Examples 1 and 2 have compressive force and adhesive force similar to those of the conventional single-phase filler, so they are less likely to depart from the injection site and have a low degree of swelling. It can be seen that it is significantly reduced. In addition, it can be seen that the injected form can be maintained for a long time from the fact that it has a high elastic modulus (G').
- mice 52 hairless mice (SKH1-hr), 6-week-old females (20 ⁇ 3 g), were obtained from Orient Bio (Korea) and acclimatized for about 1 week or more.
- ketamine 100 mg/kg
- rumpun 10 mg/kg
- the dorsal region site of Examples 1 to 2 and Comparative Examples 1 to 3 0.1 mL each was subcutaneously injected using a glass syringe.
- subjects were weighed according to designated days.
- the height of the injection site, the maximum length and volume of the injection were measured using Primos 5.8E (Canfield Scientific Inc, NJ, USA). In addition, the injection site was visually observed and a photograph was taken.
- Figure 1 is the observation of the volume change up to 42 weeks after intradermal injection of the hyaluronic acid gel.
- Comparative Example 1 which is a conventional single-phase cross-linked hyaluronic acid gel
- the initial injection volume greatly increases (about 100% increase compared to the initial injection volume) and the volume decreases significantly over time
- Examples 1 and 2 showed little or no volume change compared to the initial injection (about 10% increase compared to the initial injection volume).
- Example 1 and Example 2 can confirm that the volume loss is relatively small during 24 weeks.
- Example 1 and Example 2 show that the original volume can be maintained during injection due to small swelling in the early stage after injection, and it is confirmed that the change in volume until 24 weeks after injection is small. This excellence was confirmed.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
명칭 | 임계 변형률 (%) |
팽윤도 (%) |
평균 입도 (um) |
G' (Pa) |
점착력 (N) |
압축력 (Ns) |
주입력 (N) |
가교도 (%) |
실시예 1 | 26.01 | 56.30 | 66.0 | 611 | 6.27 | 50.09 | 16 (27G 1/2”) |
4.1 |
실시예 2 | 14.69 | 49.40 | 113.3 | 622 | 6.07 | 49.12 | 18 (27G 1/2”) |
4.13 |
비교예 1 | 4.49 | 67.10 | 261.6 | 824 | 4.82 | 47.08 | 11 (27G 1/2”) |
3.89 |
비교예 2 | 54.96 | 126.1 | 660.7 | 227 | 5.11 | 45.60 | 8 (27G) | 2.08 |
비교예 3 | 6.53 | N/A (측정불가) |
809.0 | 743 | 2.42 | 22.18 | 19 (29G) | 0.16 |
Claims (14)
- 임계 변형률(critical strain)이 10% 내지 100%이고, 팽윤도(swelling degree)가 1% 내지 100%인 히알루론산 가교체.
- 청구항 1에 있어서, 평균 입도가 50 um 내지 150 um 범위인 히알루론산 가교체.
- 청구항 1에 있어서, 탄성 계수(G')가 400 Pa 내지 2,000 Pa인 것인 히알루론산 가교체.
- 청구항 1에 있어서, 점성 계수(G”)가 100 Pa 내지 600 Pa인 것인 히알루론산 가교체.
- 청구항 1에 있어서, 압축력이 15 Nㆍs 내지 100 Nㆍs인 것인 히알루론산 가교체.
- 청구항 1에 있어서, 주입력이 1 N 내지 50 N인 것인 히알루론산 가교체.
- 청구항 1에 있어서, 이작용성 에폭시 기를 가진 가교제로 가교된 것인 히알루론산 가교체.
- 청구항 7에 있어서, 상기 이작용성 에폭시 기를 가진 가교제는 1,4-부탄디올디글리시딜 에테르, 폴리(에틸렌 글리콜) 디글리시딜 에테르, 폴리(프로필렌 글리콜) 디글리시딜 에테르, 폴리(테트라메틸렌 글리콜) 디글리시딜 에테르, 폴리글리세롤 폴리글리시딜 에테르, 글리세롤 디글리시딜 에테르, 트리에틸렌 디글리시딜에테르, 트리메틸롤프로판 트리글리시딜 에테르, 에틸렌 디글리시딜 에테르, 네오펜틸 글리콜 디글리시딜 에테르, 및 1,6-헥산디올 디글리시딜 에테르로 이루어진군으로부터 선택된 하나 이상인 것인 히알루론산 가교체.
- 청구항 1 내지 8 중 어느 한 항의 히알루론산 가교체를 포함하는 충전제 조성물.
- 청구항 9에 있어서, 히알루론산 가교체의 농도가 10 mg/mL 내지 30 mg/mL인 조성물.
- 청구항 9에 있어서, 가교되지 않은 히알루론산을 추가로 포함하지 않은 것인 조성물.
- 청구항 9에 있어서, 국소 마취제를 더 포함하는 것인 조성물.
- 청구항 9에 있어서, 주사기에 충전되어 있는 것인 조성물.
- 청구항 9에 있어서, 안면부 성형, 주름 개선, 안면 윤곽술, 가슴 성형, 가슴확대술, 성기 확대, 귀두 확대, 요실금 치료, 및 관절염 치료로 이루어진 군으로부터 선택된 하나 이상의 용도로 사용하기 위한 것인 조성물.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280043086.9A CN117500534A (zh) | 2021-06-17 | 2022-06-15 | 透明质酸交联体及包括其的填充剂组合物 |
EP22825303.5A EP4356935A1 (en) | 2021-06-17 | 2022-06-15 | Hyaluronic acid cross-linked product, and filler composition comprising same |
JP2023577285A JP2024521484A (ja) | 2021-06-17 | 2022-06-15 | ヒアルロン酸架橋体、及びそれを含む充填剤組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20210078632 | 2021-06-17 | ||
KR10-2021-0078632 | 2021-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022265380A1 true WO2022265380A1 (ko) | 2022-12-22 |
Family
ID=84525823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/008447 WO2022265380A1 (ko) | 2021-06-17 | 2022-06-15 | 히알루론산 가교체, 및 이를 포함하는 충전제 조성물 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4356935A1 (ko) |
JP (1) | JP2024521484A (ko) |
KR (1) | KR20220168990A (ko) |
CN (1) | CN117500534A (ko) |
WO (1) | WO2022265380A1 (ko) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080073419A (ko) * | 2007-02-06 | 2008-08-11 | 주식회사 핸슨바이오텍 | 의료용 히알루론산 유도체 마이크로비드 및 이의 제조 방법 |
KR20160020509A (ko) * | 2013-06-14 | 2016-02-23 | 갈데르마 소시에떼아노님 | 가교된 히알루론산 및 사이클로덱스트린을 포함하는 조성물 |
US20180223053A1 (en) * | 2015-07-27 | 2018-08-09 | Galderma Sa | A process for efficient cross-linking of hyaluronic acid |
KR102236812B1 (ko) * | 2019-07-08 | 2021-04-06 | 서울과학기술대학교 산학협력단 | 생체적합성 고분자-하이드로젤 복합체 및 이의 제조방법 |
-
2022
- 2022-06-15 KR KR1020220072529A patent/KR20220168990A/ko unknown
- 2022-06-15 JP JP2023577285A patent/JP2024521484A/ja active Pending
- 2022-06-15 WO PCT/KR2022/008447 patent/WO2022265380A1/ko active Application Filing
- 2022-06-15 CN CN202280043086.9A patent/CN117500534A/zh active Pending
- 2022-06-15 EP EP22825303.5A patent/EP4356935A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080073419A (ko) * | 2007-02-06 | 2008-08-11 | 주식회사 핸슨바이오텍 | 의료용 히알루론산 유도체 마이크로비드 및 이의 제조 방법 |
KR20160020509A (ko) * | 2013-06-14 | 2016-02-23 | 갈데르마 소시에떼아노님 | 가교된 히알루론산 및 사이클로덱스트린을 포함하는 조성물 |
US20180223053A1 (en) * | 2015-07-27 | 2018-08-09 | Galderma Sa | A process for efficient cross-linking of hyaluronic acid |
KR102236812B1 (ko) * | 2019-07-08 | 2021-04-06 | 서울과학기술대학교 산학협력단 | 생체적합성 고분자-하이드로젤 복합체 및 이의 제조방법 |
Non-Patent Citations (2)
Title |
---|
NATALIYA STOROZHYLOVA, JOSÉ CRECENTE-CAMPO, DAVID CABALEIRO, LUIS LUGO, CHRISTOPHE DUSSOUY, SANDRA SIMÕES, MADALENA MONTEIRO, CYRI: "An in situ hyaluronic acid-fibrin hydrogel containing drug-loaded nanocapsules for intra-articular treatment of inflammatory joint diseases", REGENERATIVE ENGINEERING AND TRANSLATIONAL MEDICINE, vol. 6, no. 2, 1 June 2020 (2020-06-01), pages 201 - 216, XP009541991, ISSN: 2364-4133, DOI: 10.1007/s40883-020-00154-2 * |
SEONG YUN-JEONG, LIN GUANG, KIM BYUNG JUN, KIM HYOUN-EE, KIM SUKWHA, JEONG SEOL-HA: "Hyaluronic Acid-Based Hybrid Hydrogel Microspheres with Enhanced Structural Stability and High Injectability", ACS OMEGA, ACS PUBLICATIONS, US, vol. 4, no. 9, 27 August 2019 (2019-08-27), US , pages 13834 - 13844, XP093015821, ISSN: 2470-1343, DOI: 10.1021/acsomega.9b01475 * |
Also Published As
Publication number | Publication date |
---|---|
EP4356935A1 (en) | 2024-04-24 |
JP2024521484A (ja) | 2024-05-31 |
CN117500534A (zh) | 2024-02-02 |
KR20220168990A (ko) | 2022-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2605298C2 (ru) | Композиция гиалуроновой кислоты | |
DK1699500T3 (en) | CROSS-LINKED HYALURONIC ACID COMPOSITIONS FOR TISSUE INCREASE | |
KR101672562B1 (ko) | 마취제를 포함하는 히알루론산-기반 젤 | |
AU2018228300B2 (en) | Composition For Dermal Injection | |
RU2770541C1 (ru) | Наполнитель с гиалуроновой кислотой, имеющий высокую способность лифтинга и низкую силу инъекции | |
WO2020009555A1 (ko) | 높은 점탄성 및 응집성을 동시에 갖는 히알루론산 필러 | |
US11382853B2 (en) | Hyaluronic acid dermal fillers crosslinked with citric acid, method for making same and uses thereof | |
WO2021132969A1 (ko) | 마취제, 완충 용액 및 히알루론산 하이드로겔을 포함하는 주사용 조성물 및 이의 제조방법 | |
KR20180099551A (ko) | 피부 주입용 조성물 | |
KR102107698B1 (ko) | 피부 주입용 조성물 | |
WO2021182763A1 (ko) | 히알루론산 가교체, 및 이의 용도 | |
WO2022265380A1 (ko) | 히알루론산 가교체, 및 이를 포함하는 충전제 조성물 | |
WO2024123007A1 (ko) | 퍼짐성과 안정성이 좋은 가교된 히알루론산 겔 및 그의 용도 | |
WO2020130685A1 (ko) | 우수한 필링 특성을 갖는 히알루론산 하이드로겔을 포함하는 필러 | |
WO2022149924A1 (ko) | 가교제 및 폴리올을 사용하여 가교된 가교 히알루론산 하이드로겔 및 이를 포함하는 필러 | |
EP4362993A1 (en) | Hyaluronic acid dermal fillers crosslinked with polyethylene glycol diglycidyl ether, method for making same and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22825303 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2023577285 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280043086.9 Country of ref document: CN Ref document number: 18570762 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022825303 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022825303 Country of ref document: EP Effective date: 20240117 |